Paul Tudor Jones Biotechnology

Tudor Investment Corp Et Al

$25.1 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
RCKT Rocket Pharmaceuticals, Inc.	$650M	$391,000 0.0% of portfolio	31,125	Q4 2024 Added 85.41%
ADMA Adma Biologics, Inc.	$3.26B	$387,000 0.0% of portfolio	22,614	Q4 2024 Added 110.46%
PRTA Prothena Corp Public LTD CO	$685M	$379,000 0.0% of portfolio	27,398	Q4 2024 Reduced 0.48%
RLAY Relay Therapeutics, Inc.	$393M	$355,000 0.0% of portfolio	86,357	Q4 2024 Added 7.03%
XENE Xenon Pharmaceuticals Inc.	$2.13B	$339,000 0.0% of portfolio	8,671	Q4 2024 Reduced 76.36%
KURA Kura Oncology, Inc.	$484M	$337,000 0.0% of portfolio	38,805	Q4 2024 New
PHAT Phathom Pharmaceuticals, Inc.	$172M	$276,000 0.0% of portfolio	34,049	Q4 2024 Reduced 6.42%
IMTX Immatics N.V.	$343M	$253,000 0.0% of portfolio	35,652	Q4 2024 Reduced 1.0%
KROS Keros Therapeutics, Inc.	$281M	$242,000 0.0% of portfolio	15,331	Q4 2024 Reduced 22.52%
TYRA Tyra Biosciences, Inc.	$426M	$216,000 0.0% of portfolio	15,577	Q4 2024 Reduced 40.88%
MRUS Merus N.V.	$2.14B	$213,000 0.0% of portfolio	5,075	Q4 2024 New
STOK Stoke Therapeutics, Inc.	$313M	$201,000 0.0% of portfolio	18,258	Q4 2024 New
EYPT Eye Point Pharmaceuticals, Inc.	$242M	$191,000 0.0% of portfolio	25,705	Q4 2024 New
TNGX Tango Therapeutics, Inc.	$164M	$187,000 0.0% of portfolio	60,614	Q4 2024 Reduced 4.24%
FDMT 4 D Molecular Therapeutics, Inc.	$126M	$152,000 0.0% of portfolio	27,434	Q4 2024 Reduced 3.87%
COGT Cogent Biosciences, Inc.	$450M	$131,000 0.0% of portfolio	16,819	Q4 2024 New
AMLX Amylyx Pharmaceuticals, Inc.	$227M	$126,000 0.0% of portfolio	33,687	Q4 2024 New
VNDA Vanda Pharmaceuticals Inc.	$266M	$117,000 0.0% of portfolio	24,618	Q4 2024 Added 59.46%
ZNTL Zentalis Pharmaceuticals, Inc.	$102M	$106,000 0.0% of portfolio	35,169	Q4 2024 Reduced 1.51%
PGEN Precigen, Inc.	$368M	$80,000 0.0% of portfolio	71,464	Q1 2023 Reduced 26.17%
LYEL Lyell Immunopharma, Inc.	$169M	$79,000 0.0% of portfolio	124,320	Q2 2024 Added 44.57%
ALEC Alector, Inc.	$115M	$77,000 0.0% of portfolio	40,796	Q4 2024 New
BMEA Biomea Fusion, Inc.	$73.5M	$68,000 0.0% of portfolio	17,612	Q4 2024 Reduced 1.27%
ENTA Enanta Pharmaceuticals Inc	$140M	$59,000 0.0% of portfolio	10,347	Q4 2024 Reduced 0.02%
NKTR Nektar Therapeutics	$154M	$53,000 0.0% of portfolio	57,083	Q1 2023 Reduced 78.53%
MCRB Seres Therapeutics, Inc.	$90.6M	$51,000 0.0% of portfolio	61,977	Q4 2023 Reduced 28.89%
APLT Applied Therapeutics Inc.	$27.4M	$48,000 0.0% of portfolio	57,454	Q4 2024 New
CABA Cabaletta Bio, Inc.	$53.7M	$45,000 0.0% of portfolio	20,604	Q4 2024 New
GOSS Gossamer Bio, Inc.	$108M	$41,000 0.0% of portfolio	46,464	Q1 2023 New
VTYX Ventyx Biosciences, Inc.	$80.3M	$38,000 0.0% of portfolio	17,780	Q4 2024 Reduced 12.65%
MGNX Macrogenics Inc	$138M	$35,000 0.0% of portfolio	10,950	Q4 2024 Reduced 64.9%
OCGN Ocugen, Inc.	$121M	$11,000 0.0% of portfolio	13,865	Q3 2024 New

Shares Options

Paul Tudor Jones

Paul Tudor Jones is the founder and CEO of Tudor Investment Corp, a successful investment firm that focuses on macro investing. Jones is known for his expertise in macro investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Paul Tudor Jones's portfolio

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account